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Co-infection with GB virus (GBV-C) has been as-
sociated with decreased mortality rates and improved 
outcomes in human immunodeficiency virus (HIV)-
seropositive patients, even after progression to acquired 
immunodeficiency syndrome (AIDS) (Heringlake et al. 
1998, Yeo et al. 2000). Williams et al. (2004) evaluated a 
cohort of 271 men included in the Multicenter Acquired 
Immunodeficiency Syndrome Cohort Study and demon-
strated that GBV-C viremia is associated with increased 
life expectancy among HIV-seropositive patients. In 
that study, researchers also found an intermediate pro-
tective role for antibodies specific for the E2 protein 
of GBV-C. Studies conducted in the highly active anti-
retroviral therapy (HAART) era have demonstrated that 
GBV-C is associated with lower rates of HIV rebound 
after HAART-driven virological success (Antonucci et 
al. 2005, Souza et al. 2006). Several mechanisms have 
been proposed to explain the putative effect of GBV-C 
on the course of HIV disease, such as increased secre-
tion of the chemokines regulated on activation, normal 
T cell expressed and secreted (Nattermann et al. 2003), 
macrophage inflammatory protein (MIP)-1α, MIP-1β 
and stromal cell-derived factor-1, reduced expression of 
the chemokine receptors CCR5 and CXCR4 (Xiang et al. 
2004), preservation of the Th1 cytokine profile (Sathar et 
al. 2004), activation of the interferon (IFN) gene system 
(Capobianchi et al. 2006), increased frequency of plas-
macytoid dendritic cells expressing CD80 (Lalle et al. 
2008, Baggio-Zappia & Granato 2009) and decreased T 
cell activation (Maidana-Giret et al. 2009). In contrast, 
other studies have failed to demonstrate an influence of 
GBV-C on the course of HIV infection (Quiros-Roldan 
et al. 2002, Jung et al. 2005, Van der Bij et al. 2005, Haji 
Molla Hoseini et al. 2007), while at least one report con-
cluded that GBV-C viremia tended to worsen rather than 
improve mortality among the co-infected patients (Brust 
et al. 2002). For example, Birk’s group (Birk et al. 2002) 
studied 157 patients recently infected with HIV, of whom 
36 (23%) were GBV-C RNA-positive, and demonstrated 
no significant differences between GBV-C RNA-positive 
and GBV-C RNA-negative patients in the time required 
to progress to a CD4 T cell lymphocyte count below 
200 cells/µL, the time to AIDS diagnosis or the time to 
AIDS-related death. Furthermore, controlling for known 
prognostic factors, such as age, sex, year of HIV serocon-
version, use of antiretroviral therapy and pneumocystis 
pneumonia prophylaxis did not affect any of the end-
points in this study. Studying another Swedish cohort, 
Björkman et al. (2004) followed 230 patients with serum 
samples obtained within two years of HIV diagnosis until 
initiation of antiretroviral therapy, death or their last vis-
it, with a median follow-up period of 4.3 years. At inclu-
sion, 62 (27%) patients had GBV-C viremia and 69 (30%) 
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This study was designed to assess the effect of GB virus (GBV)-C on the immune response to human immunode-
ficiency virus (HIV) in chronically HIV-infected and HIV- hepatitis C virus (HCV)-co-infected patients undergoing 
antiretroviral therapy. A cohort of 159 HIV-seropositive patients, of whom 52 were HCV-co-infected, was included. 
Epidemiological data were collected and virological and immunological markers, including the production of inter-
feron gamma (IFN-γ) and interleukin (IL)-2 by CD4, CD8 and Tγδ cells and the expression of the activation marker, 
CD38, were assessed. A total of 65 patients (40.8%) presented markers of GBV-C infection. The presence of GBV-C 
did not influence HIV and HCV replication or TCD4 and TCD8 cell counts. Immune responses, defined by IFN-γ 
and IL-2 production and CD38 expression did not differ among the groups. Our results suggest that neither GBV-C 
viremia nor the presence of E2 antibodies influence HIV and HCV viral replication or CD4 T cell counts in chroni-
cally infected patients. Furthermore, GBV-C did not influence cytokine production or CD38-driven immune activa-
tion among these patients. Although our results do not exclude a protective effect of GBV-C in early HIV disease, 
they demonstrate that this effect may not be present in chronically infected patients, who represent the majority of 
patients in outpatient clinics.
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had anti-E2 antibodies. The authors found that baseline 
GBV-C status was not associated with overall mortality, 
HIV-related mortality or development of AIDS.
Thus, whether GBV-C viremia is associated with a 
better prognosis among HIV-seropositive patients re-
mains unclear. Co-infection with other viruses, such as 
hepatitis B virus (HBV) and hepatitis C virus (HCV), 
makes the analysis of the interaction of GBV-C with HIV 
even more complex. Few studies have evaluated the effect 
of GBV-C on the disease caused by HCV and even fewer 
have assessed the effects of triple infection. Importantly, 
immune response in this profile was not evaluated. These 
considerations provide new perspectives for the investi-
gation of a potential beneficial role of GBV-C viremia in 
HIV-seropositive patients co-infected with HCV.
This study was thus designed to assess the effect of 
GBV-C viremia and the presence of GBV-C E2 antibod-
ies on immune responses in chronically HIV-infected 
and HIV-HCV-co-infected patients. The impact of 
GBV-C on HIV and HCV viremia, TCD4 and TCD8 cell 
counts, HIV-specific and nonspecific induction of type-I 
cytokines and expression of CD38 were evaluated.
PATIENTS, MATERIALS AND METHODS
Patients and methods - A cohort of 159 chronically 
HIV-infected patients, of whom 52 were HCV co-infect-
ed, from the Centre of Immune Deficiencies Control of 
the São Paulo Hospital, state of São Paulo, Brazil were 
prospectively included. Demographic data were collect-
ed and are summarised in Table. Blood samples were col-
lected to evaluate virological and immunological param-
eters and to test the patients for active GBV-C replication 
and for the presence of E2 antibodies. Written informed 
consent was obtained, and the study was approved by the 
Institutional Review Board (protocol 1296/05).
Diagnosis of GBV-C infection - Active GBV-C in-
fection is demonstrated by the presence of plasma viral 
RNA and the resolution of the infection is mediated by 
antibodies directed against the viral envelope protein E2 
(Alter et al. 2004). The simultaneous presence of viral 
RNA and antibodies specific for GBV-C E2 is a rare and 
possibly transient event (Thomas et al. 1997). Diagnosis 
of active GBV-C infection was carried out by real-time 
polymerase chain reaction (qPCR) using methods stan-
dardised in our laboratory. The 5’-untranslated region 
of GBV-C was chosen because it is a conserved region 
among all viral isolates around the world. A total of 119 
sequences available in GenBank were aligned in Se-
quencher 4.5 software (Gene Codes Corporation) to de-
sign the primers used for qPCR as previously described 
(Barbosa et al. 2009). Samples were tested for the pres-
ence of GBV-C E2 antibodies using a commercial enzy-
matic immunoassay (Roche Diagnostics GmbH).
CD4 and CD8 T cell counts - CD4 and CD8 T cell 
counts were carried out using a FACSCaliburTM flow cy-
tometer with monoclonal antibodies from Becton Dick-
inson Biosciences (BD Biosciences, San Jose, CA).
Virological parameters - HIV viral loads (VL) were 
assessed in the Laboratory of Retrovirology of the Fed-
eral University of São Paulo using the branched DNA 
HIV-1 RNA 3.0 assay (Bayer Diagnostics, Tarrytown, 
NY) with a detection limit of 50 copies/mL. HCV VLs 
were assessed in central laboratories of the São Paulo 
Hospital using a PCR assay (Amplicor 2.0 HCV monitor, 
Roche Diagnostics Systems, Basel, Switzerland).
Cell separation and stimulation for cytokine pro-
duction - Peripheral blood mononuclear cells (PBMCs) 
were isolated using the Ficoll-Paque method (GE Bio-
Science, Uppsala). PBMCs were stored in liquid ni-
trogen at a final concentration of 1 x 107/mL in vials 
containing 1 mL of fetal calf serum (FCS) (Gibco) with 
10% dimethyl sulfoxide (EMD Biosciences, La Jolla, 
CA) until use. Thawed cells were resuspended at a 
concentration of 1 x 106 cells/mL in Roswell Park Me-
morial Institute (RPMI)-1640 medium (Gibco, Grand 
Island, NY) supplemented with 10% FCS, transferred 
to a polypropylene tube and stimulated with 20 ng/mL 
phorbol myristate acetate (PMA) and 1 mM ionomy-
cin (Sigma) as a positive control or with 2 μg/μL of a 
pool of peptides derived from the Nef HIV-1 protein 
(Cat#5189, NIH) and 5 μg/μL of HIV-1III-B viral lysate 
(Advanced Biotechnologies, Columbia, Maryland) for 
specific stimulation. All samples received 1 µL co-
stimulatory molecules CD28/CD49d at a final concen-
tration of 100 µg/mL. Brefeldin-A (Sigma) was added 
to inhibit protein secretion.
Surface and intracellular staining for cytokine de-
tection - After 15-16 h of incubation, cells were washed 
twice in 10 mL staining buffer [phosphate buffered saline 
supplemented with 0.1% sodium azide (Sigma) and 1% 
FCS]. CD8-PerCP, CD3-APC-Cy7 and T cell receptor 
(TCR)γδ-FITC antibodies (BD Biosciences) were added 
and samples were incubated in the dark at room tempera-
ture (RT) for 30 min. Cells were washed and incubated 
with 750 μL permeabilisation buffer [BD FACSTM lysing 
solution (BD Biosciences) containing 0.05% Tween 20] in 
the dark at RT for 10 min. IFN-γ-PECy7 and interleukin 
(IL)-2-APC antibodies (BD Biosciences) were added and 
cells were incubated in the dark at RT for 30 min. Cells 
were washed with staining buffer and resuspended in a 
solution of 1% paraformaldehyde for flow cytometry.
CD38 activation marker staining - Thawed cells 
were washed with staining buffer and the concentration 
of viable cells was adjusted to 1 x 106 cells/mL. After 
washing, 20 μL of pooled CD8-FITC/CD38-PE/CD3-
PerCP antibodies (QuantiBRITE PETM, BD Biosciences) 
was added and cells were incubated for 15 min at RT in 
the dark. Cells were washed and resuspended in a solu-
tion of 1% paraformaldehyde for flow cytometry.
Cytokine detection - To detect cytokine expression, a 
FACSCanto flow cytometer (BD Biosciences) was used 
to acquire 70,000 events in the lymphocyte gate. Data 
were analysed using FlowJo software (Tree Star). The 
CD8+ T cell population was defined based on positive 
staining for CD3 and CD8, whereas the CD4+ T cell 
population was defined as CD8- CD3+. γδ T cells were 
defined based on positive staining for γδ TCR combined 
with the SSC parameter. Results are expressed as the 
percentages of cells producing IL-2 and IFN-γ.
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CD38 activation marker - Expression of CD38 was 
quantitatively evaluated using the QuantiBRITE PETM 
system by acquiring 70,000 events in the lymphocyte 
gate using a FACSCaliburTM flow cytometer (BD Bio-
sciences). Data were analysed using CellQuestTM soft-
ware (BD Biosciences). CD8+ T cell and CD4+ T cell 
populations were defined as previously described. The 
QuantiBRITE PETM system involves the use of phyco-
erythrin (PE)-labelled beads with known numbers of 
molecules of PE conjugated to each bead. Beads were 
used to generate a curve of mean fluorescence inten-
sity versus the number of molecules of PE/bead. This 
curve was used to determine the number of CD38 mol-
ecules per cell in samples stained with a PE-labelled 
anti-CD38 antibody. Results are expressed as the mean 
number of molecules of PE/cell.
Statistical analysis - Kolmogorov-Smirnov tests 
were performed to determine whether distributions were 
normal. Continuous variables were described as means 
plus standard deviations and discrete variables were de-
scribed as percentages. Differences among the groups 
were assessed by analysis of variance plus Tukey’s post 
hoc test. A p value of ≤ 0.05 was considered significant. 
Analysis was performed using the SPSS package 13.0 
and GraphPad Prism 5.0.
RESULTS
The mean age of the entire cohort was 43 ± 9 years, 98 
(61.6%) were men, 15 (9.4%) were intravenous drug users 
and 38 (23.8%) were alcohol abusers. The mean time of 
HIV infection diagnosis was 9.7 ± 4.8 years, while the 
mean time of HCV diagnosis was 4.8 ± 4.06 years. Of the 
159 patients, 136 (85.5%) were undergoing HAART, with 
a mean period of HAART of 7 ± 3 years (Table).
GBV-C markers - Of the 159 included patients, 65 
(40.8%) presented markers of GBV-C infection. Of these 
65 patients, 31 (19.4%) presented GBV-C viremia and 34 
(21.4%) were positive for E2 antibodies. After GBV-C 
testing, patients were separated into six distinct groups 
based on their infection profiles. 
CD4 and CD8 T cell counts - The mean CD4 T cell 
count of the entire cohort was relatively high [489 (267) 
cells/mm3] and variable, ranging from 4-1,280 cells/mm3 
(Fig. 1). The mean CD8 T cell count for the entire cohort 
was also elevated [862 (442) cells/mm3] and variable, 
ranging from 117-2,507 cells/mm3. No differences were 
observed in CD4 and CD8 T cell counts among patients 
with different infection profiles (Table).
Virological parameters - Of the 159 patients included 
in the study, 136 were undergoing HAART. Of these 136 
TABLE
Main characteristics of the studied groups according to the profile of infection
Characteristics
HIV
(n = 66)
HIV-E2+
(n = 24)
HIV-GBV-C
(n = 17)
HIV-HCV
(n = 28)
HIV-HCV-E2+
(n = 10)
HIV-HCV-GBV-C
(n = 14)
Age [years (SD)] 43.9 (10.1) 39.4 (9.2) 41.7 (9.3) 44 (7.3) 44.3 (7.5) 39.8 (8.0)
Gender
   Male [n (%)] 38 (57.6) 11 (45.8) 11 (64.7) 21 (75) 7 (70) 10 (71.4)
   Female [n (%)] 28 (42.4) 13 (54.2) 6 (35.3) 7 (25) 3 (30) 4 (29)
Risk factors for HIV [n (%)] 
   Intravenous drug use 3 (4.5) 1 (4.2) 0 (0) 9 (32.1) 2 (20) 4 (28.5)
   Homosexual contact 11 (16.7) 3 (12.5) 8 (47.1) 11 (39.2) 3 (30) 4 (28.5)
   Heterosexual contact 53 (80.3) 20 (83.3) 9 (52.9) 17 (60.8) 7 (70) 10 (71.5)
   Bisexual contact 2 (3) 1 (4.2) 0 (0) 0 (0) 0 (0) 0 (0)
Alcohol intake [n (%)] 12 (18.2) 9 (37.5) 4 (23.5) 9 (32.1) 2 (20) 2 (14.2)
Time of HIV diagnosis (years) 9 (2) 11.4 (3) 9.6 (2) 9 (1.9) 8.7 (1.9) 13.4 (2.9)
CD4 (cells/mm3) [mean (SD)] 441 (255) 544 (329) 610 (247) 514 (251) 543 (256) 382 (220)
CD8 (cells/mm3) [mean (SD)] 802 (425) 905 (434) 893 (377) 798 (481) 1,011 (529) 983 (446)
HIV viral load 
   (Log10 copies/mL) 4.01 (1.16) 4.38 (0.62) 4.3 (1.09) 3.9 (0.39) 4.3 (0.74) 2.89 (1.15)
HAART [n (%)]
   Yes 56 (84.8) 19 (79.1) 14 (82.3) 24 (85.7) 8 (80) 12 (85.7)
   No 10 (15.2) 5 (20.9) 3 (17.7) 4 (14.3) 2 (20) 2 (14.3)
HCV viral load 
   (Log10 copies/mL) [mean (SD)] - - - 5.23 (1.02) 4.65 (0.34) 5.6 (1.08)
   Interferon and ribavirin - - - 4 (14.2) 2 (20) 3 (21.4)
results of continuous variables are described as mean plus standard deviation (SD) and discrete ones as percentages. GBV-C: GB 
virus C; HAART: highly active anti-retroviral therapy; HCV: hepatitis C virus; HIV: human immunodeficiency virus.
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patients, 106 (77.9%) presented undetectable HIV VLs. 
The mean VL of the patients with detectable HIV vire-
mia was 3.9 (1.19) copies/mL log10, and VLs ranged from 
1.83-5.84. No significant differences were observed in 
HIV VLs among patients with different infection pro-
files (p = 0.075) (Fig. 1). HIV VLs did not correlate with 
GBV-C VLs (p = 0.709). Furthermore, the proportion of 
patients with undetectable HIV VLs did not significantly 
differ among the groups evaluated (χ2 = 8.11, p = 0.150) 
and exclusion of those patients who were not undergo-
ing HAART did not affect these results (χ2 = 8.71; p = 
0.121). Evaluation of GBV-C viremia and the presence 
of E2 antibodies demonstrated no significant differences 
in HCV VLs among the HIV-HCV-co-infected patients 
(p = 0.260) and no correlation was observed between 
GBV-C and HCV VLs (p = 0.238).
Intracellular detection of cytokines in T lymphocyte 
subsets - PBMCs from 135 patients were challenged with 
PMA/ionomycin and Nef peptides and PBMCs from 80 
patients were challenged with HIV-1 viral lysate. The per-
centage of TCD4, TCD8 and Tγδ cells producing IFN-γ 
and IL-2 was significantly increased after nonspecific 
stimulation with PMA/ionomycin when compared with 
the respective unstimulated controls; however, the pres-
ence of GBV-C viremia or E2 antibodies did not affect the 
percentage of cytokine-producing cells (Fig. 2). Further-
more, no changes in these results were observed when the 
nine HIV-HCV-co-infected patients who were receiving 
treatment with interferon/ribavirin were excluded from 
the analysis (data not shown). As expected, the produc-
tion of cytokines after HIV-specific stimulation was less 
robust than that elicited by PMA/ionomycin stimulation.
Fig. 1A: total CD4 T cell count according to the profile of infection; B: human immunodeficiency virus (HIV) viral load (VL) according to the 
profile of infection. Groups are represented at the legend. Each point corresponds to one patient. Horizontal bars represent mean. GBV-C: GB 
virus; HCV: hepatitis C virus.
Fig. 2: phorbol myristate acetate/ionomycin induced cytokines by lymphocyte subpopulations. Production of interferon (IFN)-γ by CD4 T cells 
(A), CD8 T cells (B), Tγδ cells and interleukin (IL)-2 (C), CD4 T cells (D), CD8 T cells (E) and Tγδ cells (F) (% of producing cells) according 
to the infection profile. Each symbol represents one response for each cytokine produced by one of the three studied cellular populations. Some 
individuals responded to more than one cellular population. Horizontal bars represent mean. GBV-C: GB virus; HCV: hepatitis C virus; HIV: 
human immunodeficiency virus.
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The percentage of cytokine-producing cells after 
antigen-specific stimulation was normalised to that ob-
served in unstimulated control cells. Normalised samples 
in which = 1% of cells produced cytokines in response to 
antigen specific stimulation were considered responsive 
(Trigona et al. 2003, Chen et al. 2005). Of the 135 patients 
challenged with Nef, 66 (48.8%) presented antigen-spe-
cific responses in at least one of the three cellular popula-
tions, with a total of 119 responses when the three cell 
populations and the two cytokines were considered indi-
vidually. Among the responders, 24 (36.4%) were HIV-
monoinfected, 14 (21.2%) were HIV-HCV-co-infected, 
13 (19.7%) were HIV-E2+, eight (12.1%) were HIV-GBV-
C-co-infected, five (7.6%) were HIV-HCV-E2+ and two 
(3%) were HIV-HCV-GBV-C-triple-infected. No differ-
ences were observed in any of the lymphocyte popula-
tions in the proportion of cells responding to Nef peptides 
by producing IFN-γ (p = 0.676, p = 0.566, p = 0.540) or 
IL-2 (p = 0.764, p = 0.321, p = 0.123) among patients with 
different infection profiles (Fig. 3).
Of the 80 patients challenged with HIV-1 viral lysate, 
35 (43.7%) presented specific responses in at least one 
of the three lymphocyte populations. Of these patients, 
eight (22.8%) were HIV-monoinfected, 14 (40%) were 
co-infected with HCV, six (17.1%) were HIV-E2+, one 
(2.8%) was HIV-GBV-C viremic, four (11.4%) were 
HIV-HCV-E2+ and two (5.7%) were triple-infected, with 
a total of 66 responses (Fig. 4). No differences in IFN-γ 
(p = 0.567, p = 0.766, p = 0.546) and IL-2 (p = 0.786, p = 
0.564, p = 0.856) production were observed in T CD4, T 
CD8 and Tγδ populations among the patient groups.
CD38 activation marker - Expression of CD38 on 
CD4 and CD8 T cells was positively correlated with 
HIV VLs (p = 0.001, p = 0.017). The expression of CD38 
on CD4 and CD8 T cells did not correlate with GBV-C 
VLs (p = 0.588, p = 0.753). No differences in CD38 ex-
pression on CD4 or CD8 T cells were observed among 
patients with different infection profiles (Fig. 5). 
DISCUSSION
Epidemiological studies have associated the pres-
ence of GBV-C RNA with slower progression to AIDS, 
decreased mortality rates and increased survival of HIV-
seropositive patients after the development of AIDS. 
Our results, however, demonstrate that neither GBV-C 
viremia nor the presence of E2 antibodies influenced 
these parameters in either HIV-seropositive or chroni-
cally HIV-HCV-co-infected patients. 
Our results thus demonstrate that GBV-C does not 
affect CD4 and CD8 T cell counts or HIV VLs. Previ-
ous studies of the impact of GBV-C viremia on CD4 T 
cell counts and HIV VLs among HIV-seropositive pa-
tients have provided inconsistent results. Some studies 
have demonstrated increased CD4 T cell counts and de-
creased HIV VLs among HIV-GBV-C-co-infected pa-
tients when compared to those in HIV-monoinfected pa-
tients (Heringlake et al. 1998, Lefrere et al. 1999, Xiang 
et al. 2001, Li et al. 2006). Other studies, however, have 
not corroborated these findings, as no effect of GBV-C 
viremia on these parameters was observed. These dis-
crepancies could be a consequence of differences in the 
populations included, the stage of the HIV disease, the 
presence of other infections such as HBV and HCV or 
the standard of care of HIV therapy. Our study evalu-
ated a cohort of chronically infected patients of whom 
the majority was undergoing HAART therapy. In addi-
tion, patients carrying HCV were evaluated as a sepa-
rate group. The mean time of HIV infection diagnosis 
among the entire cohort was 9.7 years, while the mean 
Fig. 3: antigen specific response to Nef peptides challenge. Production of interferon (IFN)-γ CD4 T cells(A), CD8 T cells (B), Tγδ cells (C) and interleu-
kin (IL)-2 CD4 T cells (D), CD8 T cells (E) and Tγδ cells (F) (% of producing cells) according to the infection profile. Each symbol represents one res- 
ponse for each cytokine produced by one of the three studied cellular populations. Some individuals responded to more than one cellular population. 
A cut-off of 1% was used to define the responsive individuals. GBV-C: GB virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus.
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time of HCV infection diagnosis among all co-infected 
patients was 4.8 years. Careful evaluation of the previ-
ous studies assessing the effect of GBV-C viremia on 
HIV infection reveals that some studies did not report 
the time of HIV infection diagnosis and others included 
patients at different stages of the HIV disease. Taken 
together, the findings reported in these studies suggest 
that any potentially positive effect of GBV-C viremia on 
HIV infection may not be extended to all HIV-seroposi-
tive patients and may be influenced by the stage of HIV 
disease. Considering that the patients in our study were 
chronically infected and that GBV-C viremia could be 
rapidly reversed in these immunosuppressed patients, it 
is reasonable to hypothesise that the patients in our study 
were first infected with HIV and then acquired GBV-C. 
This sequence of viral infections may preclude some pu-
tative protective effects of GBV-C. In an in vitro study, 
Xiang et al. (2001) previously demonstrated that HIV 
replication was inhibited more efficiently when GBV-C 
infection preceded HIV infection. 
Antiretrovirals influence the parameters evaluated 
in this study and could thus be a confounding factor. In 
this study, 85% of the included patients were undergo-
ing HAART and the proportion of untreated patients 
was not significantly different among the groups strati-
fied for analysis based on the infection profile. In addi-
tion, the profile of antiretroviral treatment did not con-
sistently differ among the included patients. Previous 
studies have suggested that GBV-C viremia influences 
the response to antiretroviral therapy. Rodriguez et al. 
(2003) showed that HIV-GBV-C-co-infected patients 
had an increased incidence of undetectable HIV VLs af-
Fig. 5: expression of CD38 activation marker on CD4 (A) and CD8 T cells (B) according to the profile of infection. Groups are represented at 
the legend. Each point corresponds to one patient. Horizontal bars represent mean. GBV-C: GB virus; HCV: hepatitis C virus; HIV: human 
immunodeficiency virus.
Fig. 4: antigen specific response to human immunodeficiency virus (HIV) viral lysate peptides challenge. Production of interferon (IFN)-γ 
CD4 T cells (A), CD8 T cells (B), Tγδ cells (C) and interleukin (IL)-2 CD4 T cells (D), CD8 T cells (E) and Tγδ cells (F) (% of producing cells) 
according to the infection profile. Each symbol represents one response for each cytokine produced by one of the three studied cellular popula-
tions. Some individuals responded to more than one cellular population. A cut-off of 1% was used to define the responsive individuals. GBV-C: 
GB virus; HCV: hepatitis C virus.
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ter HAART initiation. In contrast, Brumme et al. (2002) 
also evaluated the effect of GBV-C viremia on patients 
undergoing HAART and found lower HIV VLs at in-
clusion; however, no effect on the time at which viro-
logical success was achieved was observed. Our results 
suggest that GBV-C did not influence HIV replication 
in chronically infected patients, as no differences in the 
proportion of patients undergoing HAART that achieved 
virological success were observed among patients with 
different infection profiles. In addition, GBV-C viremia 
did not influence HCV replication, as no differences in 
HCV VLs were observed.
The central focus of this study was to evaluate the 
effect of GBV-C viremia and the presence of E2 antibod-
ies on the immune response in HIV-infected and HIV-
HCV-co-infected patients. To this end, we evaluated 
the production of the Th1 cytokines IFN-γ and IL-2 by 
CD4 and CD8 T cells and Tγδ cells after specific im-
mune stimulation. To the best of our knowledge, this 
study provides the first analysis of the activation of Tγδ 
cells in patients with these infection profiles. The role of 
GBV-C viremia in the maintenance of an intact Th1 pro-
file among HIV-seropositive patients was first proposed 
by Nunnari et al. (2003), who evaluated a panel of cy-
tokines in a cohort of asymptomatic patients and found 
a positive influence of GBV-C viremia. Taking into ac-
count the results obtained by Nunnari et al. (2003), we 
hypothesised that GBV-C viremia could preserve the 
cellular immune response to HIV and expected to ob-
serve increased production of the Th1 cytokines IFN-γ 
and IL-2 in the co-infected patients.
Stimulation with PMA and ionomycin triggers a 
strong production of cytokines in vitro and is often used 
to evaluate immune responses when specific stimulation 
is not feasible because of the capacity of these stimuli 
to amplify the profile of the responses seen in vivo (Vi-
tale et al. 2000, Eylar et al. 2001). In the present study, 
we found increased production of IFN-γ and IL-2 after 
nonspecific stimulation with PMA and ionomycin, dem-
onstrating that the capacity to respond with synthesis of 
type-1 cytokines is preserved in these patients; however, 
no differences in the production of cytokines by TCD4, 
TCD8 and Tγδ cells were observed in patients with dif-
ferent infection profiles, regardless of the presence of 
GBV-C viremia or E2 antibodies. 
Specific cellular immune responses mediated by T 
cells play an important role in controlling HIV infec-
tion and efficient T cell responses can delay disease pro-
gression. The T cell antigen-specific repertoire declines 
throughout the course of HIV infection, with dramatic 
changes in the CD8 T cell phenotype (Alter et al. 2004). 
Data from studies of HIV-infected patients have demon-
strated a decline in specific cellular immune responses 
as the disease progresses and these changes have been 
associated with the HIV VL (Legrand et al. 1997, Kou-
signian et al. 2003). Our results demonstrated a posi-
tive correlation between the HIV VL and Nef-specific 
responses in CD4 and CD8 T cells, suggesting a cer-
tain degree of preservation of immunity to HIV anti-
gens. This preservation of immunity was independent of 
GBV-C, as no differences were observed in these param-
eters among patients with different infection profiles. 
Some patients demonstrated efficient Tγδ cell responses 
to specific stimulation with viral lysate. In addition to 
IFN-γ, Tγδ cells produced high levels of IL-2; however, 
production of these cytokines did not differ among pa-
tients with different infection profiles, demonstrating no 
influence of GBV-C on Tγδ cell responses. 
In an attempt to assess the influence of GBV-C vire-
mia or the presence of E2 antibodies on HIV disease, we 
quantitatively assessed the expression of CD38 in CD4 
and CD8 T cells. A recent report showed decreased lev-
els of CD38 expression among GBV-C viremic patients 
(Maidana-Giret et al. 2009). In contrast, our findings do 
not corroborate these results; instead, we demonstrated 
that GBV-C viremia did not decrease cellular activation 
in chronically HIV-infected or triple-infected patients. 
These divergent findings could be a result of the stage of 
the HIV disease in the included patients, as the patients 
included in our study were chronically infected, and 
those included in previous studies were acutely infected. 
In addition, the methodologies used in these studies dif-
fered greatly. While the authors of the previous studies 
expressed their results as the percentage of CD38+ cells, 
our results are quantitative and are presented as the mean 
number of CD38 molecules expressed per cell. Expres-
sion of CD38 was widely variable among the patients, 
reflecting the variable immune status characteristic of 
chronically infected patients.
Our results suggest that neither GBV-C viremia nor 
E2 antibodies appear to influence viral replication of 
HIV or HCV or CD4 T cell counts in chronically infect-
ed patients. Furthermore, GBV-C infection did not in-
fluence the immune response as measured by cytokine 
production or CD38-driven immune activation in these 
patients. Our results do not exclude a protective effect of 
GBV-C in HIV disease but show that this effect is not 
present in chronically infected patients, who represent 
the majority of patients seen in outpatient clinics. Sev-
eral factors, such as differences in the study populations, 
the stage of HIV infection and the time of GBV-C acqui-
sition, may account for the discrepant results reported by 
different research groups.
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